The PRIMARY score has been included in the recent EANM procedural recommendations and builds upon PSMA PET/CT, a modality now endorsed by the EAU 2024 guideline as the preferred staging tool in high-risk prostate cancer [12,13]. This evidence concerns the gene FOLH1 and prostate carcinoma.